Barry Davis - Publications

Affiliations: 
The University of Texas School of Public Health 
Area:
Public Health, Biostatistics Biology

157 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Kostis WJ, Sargsyan D, Mekkaoui C, Moreyra AE, Cabrera J, Cosgrove NM, Sedjro JE, Kostis JB, Cushman WC, Pantazopoulos JS, Pressel SL, Davis BR. Association of orthostatic hypertension with mortality in the Systolic Hypertension in the Elderly Program. Journal of Human Hypertension. PMID 30804464 DOI: 10.1038/s41371-019-0180-4  0.32
2019 Berkelmans GFN, Gudbjörnsdottir S, Visseren FLJ, Wild SH, Franzen S, Chalmers J, Davis BR, Poulter NR, Spijkerman AM, Woodward M, Pressel SL, Gupta AK, van der Schouw YT, Svensson AM, van der Graaf Y, et al. Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus. European Heart Journal. PMID 30629157 DOI: 10.1093/eurheartj/ehy839  0.32
2018 Barzilay JI, Lai D, Davis BR, Pressel S, Pervin HE, Arnett D. The Interaction of a Diabetes Gene Risk Score With Three Different Antihypertensive Medications for Incident Glucose Level Elevation. American Journal of Hypertension. PMID 30590387 DOI: 10.1093/ajh/hpy199  0.32
2018 Haywood LJ, Davis BR, Piller LB, Simpson LM, Ghosh A, Einhorn PT, Ford CE, Probstfield JL, Soliman EZ, Wright JT. Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT. Journal of the National Medical Association. 110: 343-351. PMID 30126559 DOI: 10.1016/j.jnma.2017.07.003  0.32
2018 Barzilay JI, Davis BR, Ghosh A, Pressel SL, Rahman M, Einhorn PT, Cushman WC, Whelton PK, Wright JT. Rapid eGFR change as a determinant of cardiovascular and renal disease outcomes and of mortality in hypertensive adults with and without type 2 diabetes. Journal of Diabetes and Its Complications. PMID 30030011 DOI: 10.1016/j.jdiacomp.2018.07.003  0.32
2018 Barzilay JI, Davis BR, Pressel SL, Ghosh A, Rahman M, Einhorn PT, Cushman WC, Whelton PK, Wright JT. The Effects of eGFR Change on CVD, Renal, and Mortality Outcomes in a Hypertensive Cohort Treated With 3 Different Antihypertensive Medications. American Journal of Hypertension. PMID 29360915 DOI: 10.1093/ajh/hpx223  0.32
2017 Haywood LJ, Davis BR, Piller LB, Cushman WC, Cutler JA, Ford CE, Simpson LM, Ghosh A, Soliman EZ, Wright JT. Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT. Journal of the National Medical Association. 109: 172-181. PMID 28987246 DOI: 10.1016/j.jnma.2017.02.005  0.32
2017 Barzilay JI, Davis BR, Pressel SL, Ghosh A, Puttnam R, Margolis KL, Whelton PK. The Impact of Antihypertensive Medications on Bone Mineral Density and Fracture Risk. Current Cardiology Reports. 19: 76. PMID 28752275 DOI: 10.1007/s11886-017-0888-0  0.32
2017 Dhruva SS, Huang C, Spatz ES, Coppi AC, Warner F, Li SX, Lin H, Xu X, Furberg CD, Davis BR, Pressel SL, Coifman RR, Krumholz HM. Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). Hypertension (Dallas, Tex. : 1979). PMID 28559399 DOI: 10.1161/HYPERTENSIONAHA.117.09221  0.32
2017 Han BH, Sutin D, Williamson JD, Davis BR, Piller LB, Pervin H, Pressel SL, Blaum CS. Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial. Jama Internal Medicine. PMID 28531241 DOI: 10.1001/jamainternmed.2017.1442  0.32
2016 Bangalore S, Davis BR, Cushman WC, Pressel SL, Muntner PM, Calhoun DA, Kostis JB, Whelton PK, Probstfield JL, Rahman M, Black HR. Treatment Resistant Hypertension and Outcomes based on Randomized Treatment Group in ALLHAT. The American Journal of Medicine. PMID 27984005 DOI: 10.1016/j.amjmed.2016.10.002  0.32
2016 Ernst ME, Davis BR, Soliman EZ, Prineas RJ, Okin PM, Ghosh A, Cushman WC, Einhorn PT, Oparil S, Grimm RH. Electrocardiographic measures of left ventricular hypertrophy in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Journal of the American Society of Hypertension : Jash. 10: 930-938.e9. PMID 27938852 DOI: 10.1016/j.jash.2016.10.010  0.32
2016 Chen DP, Davis BR, Simpson LM, Cushman WC, Cutler JA, Dobre M, Ford CE, Louis GT, Muntner P, Oparil S, Piller LB, Pressel SL, Sarnak MJ, Whelton PK, Wright JT, et al. Association between chronic kidney disease and cancer mortality: A report from the ALLHAT. Clinical Nephrology. PMID 27900942 DOI: 10.5414/CN108949  0.32
2016 Puttnam R, Davis BR, Pressel SL, Whelton PK, Cushman WC, Louis GT, Margolis KL, Oparil S, Williamson J, Ghosh A, Einhorn PT, Barzilay JI. Association of 3 Different Antihypertensive Medications With Hip and Pelvic Fracture Risk in Older Adults: Secondary Analysis of a Randomized Clinical Trial. Jama Internal Medicine. PMID 27893045 DOI: 10.1001/jamainternmed.2016.6821  0.32
2016 Whelton PK, Einhorn PT, Muntner P, Appel LJ, Cushman WC, Diez Roux AV, Ferdinand KC, Rahman M, Taylor HA, Ard J, Arnett DK, Carter BL, Davis BR, Freedman BI, Cooper LA, et al. Research Needs to Improve Hypertension Treatment and Control in African Americans. Hypertension (Dallas, Tex. : 1979). PMID 27620388 DOI: 10.1161/HYPERTENSIONAHA.116.07905  0.32
2016 Whittle J, Yamal JM, Williamson JD, Ford CE, Probstfield JL, Beard BL, Marginean H, Hamilton BP, Suhan PS, Davis BR. Clinical and demographic correlates of medication and visit adherence in a large randomized controlled trial. Bmc Health Services Research. 16: 236. PMID 27391223 DOI: 10.1186/s12913-016-1471-x  0.32
2016 Dewland TA, Soliman EZ, Davis BR, Magnani JW, Yamal JM, Piller LB, Haywood LJ, Alonso A, Albert CM, Marcus GM. Effect of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) on Conduction System Disease. Jama Internal Medicine. PMID 27367818 DOI: 10.1001/jamainternmed.2016.2502  0.32
2016 Barzilay JI, Whelton PK, Davis BR. Does renin angiotensin system blockade deserve preferred status over other anti-hypertensive medications for the treatment of people with diabetes? Annals of Translational Medicine. 4: 202. PMID 27294098 DOI: 10.21037/atm.2016.05.24  0.32
2016 Luce BR, Connor JT, Broglio KR, Mullins CD, Ishak KJ, Saunders E, Davis BR. Using Bayesian Adaptive Trial Designs for Comparative Effectiveness Research: A Virtual Trial Execution. Annals of Internal Medicine. PMID 27273013 DOI: 10.7326/M15-0823  0.32
2016 Kronish IM, Lynch AI, Oparil S, Whittle J, Davis BR, Simpson LM, Krousel-Wood M, Cushman WC, Chang TI, Muntner P. The Association Between Antihypertensive Medication Nonadherence and Visit-to-Visit Variability of Blood Pressure: Findings From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Hypertension. PMID 27217410 DOI: 10.1161/HYPERTENSIONAHA.115.06960  0.32
2016 Kaasenbrood L, Poulter NR, Sever PS, Colhoun HM, Livingstone SJ, Boekholdt SM, Pressel SL, Davis BR, van der Graaf Y, Visseren FL. Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes Study. Circulation. Cardiovascular Quality and Outcomes. PMID 27174798 DOI: 10.1161/CIRCOUTCOMES.115.001980  0.32
2016 Catalá-López F, Macías Saint-Gerons D, González-Bermejo D, Rosano GM, Davis BR, Ridao M, Zaragoza A, Montero-Corominas D, Tobías A, de la Fuente-Honrubia C, Tabarés-Seisdedos R, Hutton B. Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses. Plos Medicine. 13: e1001971. PMID 26954482 DOI: 10.1371/journal.pmed.1001971  0.32
2016 Whittle J, Lynch AI, Tanner RM, Simpson LM, Davis BR, Rahman M, Whelton PK, Oparil S, Muntner P. Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT. Clinical Journal of the American Society of Nephrology : Cjasn. PMID 26912544 DOI: 10.2215/CJN.04660415  0.32
2016 Probstfield JL, Hirsch IB, Davis BR, Ahmann A, Bergenstal R, Gilbert M, Kingry C, Khakpour D, Lai D, Pressel SL, Branch KR, Riddle M, O'Brien KD. Glucose variability in a 26-week randomized comparison of mealtime treatment with rapid-acting insulin versus glp-1 agonist in participants with type 2 diabetes at high cardiovascular risk Diabetes Care. 39: 973-981. DOI: 10.2337/dc15-2782  0.32
2016 Zhang Q, Lai D, Davis BR. Repeated confidence intervals and prediction intervals using stochastic curtailment under fractional Brownian motion Communications in Statistics - Theory and Methods. 45: 4295-4306. DOI: 10.1080/03610926.2014.919400  0.32
2016 Do AN, Lynch AI, Claas SA, Boerwinkle E, Davis BR, Ford CE, Eckfeldt JH, Tiwari HK, Arnett DK, Irvin MR. The effects of genes implicated in cardiovascular disease on blood pressure response to treatment among treatment-naive hypertensive African Americans in the GenHAT study Journal of Human Hypertension. DOI: 10.1038/jhh.2015.121  0.32
2015 Alderman MH, Davis BR, Piller LB, Ford CE, Baraniuk MS, Pressel SL, Assadi MA, Einhorn PT, Haywood LJ, Ilamathi E, Oparil S, Retta TM. Should Antihypertensive Treatment Recommendations Differ in Patients With and Without Coronary Heart Disease? (from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT]). The American Journal of Cardiology. PMID 26589819 DOI: 10.1016/j.amjcard.2015.10.012  0.32
2015 Wood JC, Cohen AR, Pressel SL, Aygun B, Imran H, Luchtman-Jones L, Thompson AA, Fuh B, Schultz WH, Davis BR, Ware RE. Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology. PMID 26523836 DOI: 10.1111/bjh.13791  0.32
2015 Bis JC, Sitlani C, Irvin R, Avery CL, Smith AV, Sun F, Evans DS, Musani SK, Li X, Trompet S, Krijthe BP, Harris TB, Quibrera PM, Brody JA, Demissie S, ... Davis BR, et al. Drug-Gene Interactions of Antihypertensive Medications and Risk of Incident Cardiovascular Disease: A Pharmacogenomics Study from the CHARGE Consortium. Plos One. 10: e0140496. PMID 26516778 DOI: 10.1371/journal.pone.0140496  0.32
2015 Muntner P, Whittle J, Lynch AI, Colantonio LD, Simpson LM, Einhorn PT, Levitan EB, Whelton PK, Cushman WC, Louis GT, Davis BR, Oparil S. Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study. Annals of Internal Medicine. 163: 329-38. PMID 26215765 DOI: 10.7326/M14-2803  0.32
2015 Wood JC, Pressel S, Rogers ZR, Odame I, Kwiatkowski JL, Lee MT, Owen WC, Cohen AR, St Pierre T, Heeney MM, Schultz WH, Davis BR, Ware RE. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology. PMID 26087998 DOI: 10.1002/ajh.24089  0.32
2015 Einhorn PT, Whelton PK, Davis BR, Wright JT, Cushman WC, Zieman SJ. Real-world evidence supports optimally dosed thiazide-type diuretics as preferred in treatment regimens of older adults with hypertension. Journal of the American Geriatrics Society. 63: 1045-7. PMID 25989579 DOI: 10.1111/jgs.13415  0.32
2015 Preiss D, Campbell RT, Murray HM, Ford I, Packard CJ, Sattar N, Rahimi K, Colhoun HM, Waters DD, LaRosa JC, Amarenco P, Pedersen TR, Tikkanen MJ, Koren MJ, Poulter NR, ... ... Davis BR, et al. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. European Heart Journal. 36: 1536-46. PMID 25802390 DOI: 10.1093/eurheartj/ehv072  0.32
2015 Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, ... Davis B, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 385: 1397-405. PMID 25579834 DOI: 10.1016/S0140-6736(14)61368-4  0.32
2015 Zhang Q, Lai D, Davis BR. Stochastically curtailed tests under fractional brownian motion Communications in Statistics - Theory and Methods. 44: 1053-1064. DOI: 10.1080/03610926.2012.754469  0.32
2015 Teng M, Lin L, Zhao YJ, Khoo AL, Davis BR, Yong QW, Yeo TC, Lim BP. Statins for Primary Prevention of Cardiovascular Disease in Elderly Patients: Systematic Review and Meta-Analysis Drugs and Aging. 32: 649-661. DOI: 10.1007/s40266-015-0290-9  0.32
2015 Barzilay JI, Whelton PK, Davis BR. The glycemic consequences of antihypertensive medications Pathophysiology and Pharmacotherapy of Cardiovascular Disease. 935-948. DOI: 10.1007/978-3-319-15961-4_44  0.32
2014 Yamal JM, Oparil S, Davis BR, Alderman MH, Calhoun DA, Cushman WC, Fendley HF, Franklin SS, Habib GB, Pressel SL, Probstfield JL, Sastrasinh S. Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT. Journal of the American Society of Hypertension : Jash. 8: 808-19. PMID 25455006 DOI: 10.1016/j.jash.2014.08.003  0.32
2014 Muntner P, Davis BR, Cushman WC, Bangalore S, Calhoun DA, Pressel SL, Black HR, Kostis JB, Probstfield JL, Whelton PK, Rahman M. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 64: 1012-21. PMID 25259745 DOI: 10.1161/HYPERTENSIONAHA.114.03850  0.32
2014 Sørensen IF, Vazquez AI, Irvin MR, Sørensen P, Davis BR, Ford CE, Boerwinkle E, Eckfeldt JH, Arnett DK. Pharmacogenetic effects of 'candidate gene complexes' on stroke in the GenHAT study. Pharmacogenetics and Genomics. 24: 556-63. PMID 25171760 DOI: 10.1097/FPC.0000000000000088  0.32
2014 Piller LB, Simpson LM, Baraniuk S, Habib GB, Rahman M, Basile JN, Dart RA, Ellsworth AJ, Fendley H, Probstfield JL, Whelton PK, Davis BR. Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT. Journal of General Internal Medicine. 29: 1475-83. PMID 25002161 DOI: 10.1007/s11606-014-2947-1  0.32
2014 Reisin E, Graves JW, Yamal JM, Barzilay JI, Pressel SL, Einhorn PT, Dart RA, Retta TM, Saklayen MG, Davis BR. Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT. Journal of Hypertension. 32: 1503-13; discussion . PMID 24842697 DOI: 10.1097/HJH.0000000000000204  0.32
2014 Swerdel JN, Janevic TM, Cabrera J, Cosgrove NM, Sedjro JE, Pressel SL, Davis BR, Kostis JB. Rapid decreases in blood pressure from antihypertensive treatment were associated with increased cancer mortality in the Systolic Hypertension in the Elderly Program. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 23: 1589-97. PMID 24832873 DOI: 10.1158/1055-9965.EPI-14-0085  0.32
2014 Shah RV, Abbasi SA, Yamal JM, Davis BR, Barzilay J, Einhorn PT, Goldfine A. Impaired fasting glucose and body mass index as determinants of mortality in ALLHAT: is the obesity paradox real? Journal of Clinical Hypertension (Greenwich, Conn.). 16: 451-8. PMID 24779706 DOI: 10.1111/jch.12325  0.32
2014 Muntner P, Levitan EB, Lynch AI, Simpson LM, Whittle J, Davis BR, Kostis JB, Whelton PK, Oparil S. Effect of chlorthalidone, amlodipine, and lisinopril on visit-to-visit variability of blood pressure: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Journal of Clinical Hypertension (Greenwich, Conn.). 16: 323-30. PMID 24739073 DOI: 10.1111/jch.12290  0.32
2014 Kostis WJ, Cabrera J, Messerli FH, Cheng JQ, Sedjro JE, Cosgrove NM, Swerdel JN, Deng Y, Davis BR, Kostis JB. Competing cardiovascular and noncardiovascular risks and longevity in the systolic hypertension in the elderly program. The American Journal of Cardiology. 113: 676-81. PMID 24388619 DOI: 10.1016/j.amjcard.2013.11.013  0.32
2014 Barzilay JI, Davis BR, Whelton PK. The glycemic effects of antihypertensive medications. Current Hypertension Reports. 16: 410. PMID 24338675 DOI: 10.1007/s11906-013-0410-z  0.32
2014 Kostis JB, Sedjro JE, Cabrera J, Cosgrove NM, Pantazopoulos JS, Kostis WJ, Pressel SL, Davis BR. Visit-to-visit blood pressure variability and cardiovascular death in the Systolic Hypertension in the Elderly Program. Journal of Clinical Hypertension (Greenwich, Conn.). 16: 34-40. PMID 24325609 DOI: 10.1111/jch.12230  0.32
2013 Margolis KL, Davis BR, Baimbridge C, Ciocon JO, Cuyjet AB, Dart RA, Einhorn PT, Ford CE, Gordon D, Hartney TJ, Julian Haywood L, Holtzman J, Mathis DE, Oparil S, Probstfield JL, et al. Author response to lipid-lowering in African Americans in ALLHAT-optimism bias? Journal of Clinical Hypertension (Greenwich, Conn.). 15: 941. PMID 24299695 DOI: 10.1111/jch.12220  0.32
2013 Lynch AI, Irvin MR, Davis BR, Ford CE, Eckfeldt JH, Arnett DK. Genetic and Adverse Health Outcome Associations with Treatment Resistant Hypertension in GenHAT. International Journal of Hypertension. 2013: 578578. PMID 24288596 DOI: 10.1155/2013/578578  0.32
2013 Phillips W, Piller LB, Williamson JD, Whittle J, Jafri SZ, Ford CE, Einhorn PT, Oparil S, Furberg CD, Grimm RH, Alderman MH, Davis BR, Probstfield JL. Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHAT. Journal of Clinical Hypertension (Greenwich, Conn.). 15: 825-32. PMID 24283598 DOI: 10.1111/jch.12180  0.32
2013 Connor JT, Luce BR, Broglio KR, Ishak KJ, Mullins CD, Vanness DJ, Fleurence R, Saunders E, Davis BR. Do Bayesian adaptive trials offer advantages for comparative effectiveness research? Protocol for the RE-ADAPT study. Clinical Trials (London, England). 10: 807-27. PMID 23983160 DOI: 10.1177/1740774513497293  0.32
2013 Margolis KL, Davis BR, Baimbridge C, Ciocon JO, Cuyjet AB, Dart RA, Einhorn PT, Ford CE, Gordon D, Hartney TJ, Julian Haywood L, Holtzman J, Mathis DE, Oparil S, Probstfield JL, et al. Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). Journal of Clinical Hypertension (Greenwich, Conn.). 15: 542-54. PMID 23889716 DOI: 10.1111/jch.12139  0.32
2013 Rahman M, Baimbridge C, Davis BR, Barzilay JI, Basile JN, Henriquez MA, Huml A, Kopyt N, Louis GT, Pressel SL, Rosendorff C, Sastrasinh S, Stanford C. Pravastatin and cardiovascular outcomes stratified by baseline eGFR in the lipid- lowering component of ALLHAT. Clinical Nephrology. 80: 235-48. PMID 23816477 DOI: 10.5414/CN107922  0.32
2013 Oparil S, Davis BR, Cushman WC, Ford CE, Furberg CD, Habib GB, Haywood LJ, Margolis K, Probstfield JL, Whelton PK, Wright JT. Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex. Hypertension. 61: 977-86. PMID 23529173 DOI: 10.1161/HYPERTENSIONAHA.111.00213  0.32
2013 Proschan M, Ford CE, Cutler JA, Graumlich JF, Pavlik V, Cushman WC, Davis BR, Alderman MH, Gordon D, Furberg CD, Franklin SS, Blumenthal SS, Castaldo RS, Preston RA. How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure? Statistics in Medicine. 32: 884-97. PMID 22961832 DOI: 10.1002/sim.5580  0.32
2013 Lynch AI, Irvin MR, Boerwinkle E, Davis BR, Vaughan LK, Ford CE, Aissani B, Eckfeldt JH, Arnett DK, Shrestha S. RYR3 gene polymorphisms and cardiovascular disease outcomes in the context of antihypertensive treatment. The Pharmacogenomics Journal. 13: 330-4. PMID 22664477 DOI: 10.1038/tpj.2012.22  0.32
2012 Drawz PE, Baraniuk S, Davis BR, Brown CD, Colon PJ, Cujyet AB, Dart RA, Graumlich JF, Henriquez MA, Moloo J, Sakalayen MG, Simmons DL, Stanford C, Sweeney ME, Wong ND, et al. Cardiovascular risk assessment: addition of CKD and race to the Framingham equation. American Heart Journal. 164: 925-31.e2. PMID 23194494 DOI: 10.1016/j.ahj.2012.09.003  0.32
2012 Rahman M, Ford CE, Cutler JA, Davis BR, Piller LB, Whelton PK, Wright JT, Barzilay JI, Brown CD, Colon PJ, Fine LJ, Grimm RH, Gupta AK, Baimbridge C, Haywood LJ, et al. Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR. Clinical Journal of the American Society of Nephrology : Cjasn. 7: 989-1002. PMID 22490878 DOI: 10.2215/CJN.07800811  0.32
2012 Zhang X, Lynch AI, Davis BR, Ford CE, Boerwinkle E, Eckfeldt JH, Leiendecker-Foster C, Arnett DK. Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study. Plos One. 7: e34217. PMID 22470539 DOI: 10.1371/journal.pone.0034217  0.32
2012 Alderman MH, Piller LB, Ford CE, Probstfield JL, Oparil S, Cushman WC, Einhorn PT, Franklin SS, Papademetriou V, Ong ST, Eckfeldt JH, Furberg CD, Calhoun DA, Davis BR. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 59: 926-33. PMID 22431578 DOI: 10.1161/HYPERTENSIONAHA.111.180554  0.32
2012 Barzilay JI, Davis BR, Pressel SL, Cutler JA, Einhorn PT, Black HR, Cushman WC, Ford CE, Margolis KL, Moloo J, Oparil S, Piller LB, Simmons DL, Sweeney ME, Whelton PK, et al. Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study. Circulation. Cardiovascular Quality and Outcomes. 5: 153-62. PMID 22396585 DOI: 10.1161/CIRCOUTCOMES.111.962522  0.32
2012 Lynch AI, Eckfeldt JH, Davis BR, Ford CE, Boerwinkle E, Leiendecker-Foster C, Arnett DK. Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT study. Pharmacogenetics and Genomics. 22: 355-66. PMID 22388798 DOI: 10.1097/FPC.0b013e3283516ff8  0.32
2012 Cushman WC, Davis BR, Pressel SL, Cutler JA, Einhorn PT, Ford CE, Oparil S, Probstfield JL, Whelton PK, Wright JT, Alderman MH, Basile JN, Black HR, Grimm RH, Hamilton BP, et al. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Journal of Clinical Hypertension (Greenwich, Conn.). 14: 20-31. PMID 22235820 DOI: 10.1111/j.1751-7176.2011.00568.x  0.32
2012 Tilley BC, Davis BR. Secondary analyses in cardiovascular clinical trials - statistical and other considerations. Introduction. Progress in Cardiovascular Diseases. 54: 329. PMID 22225998 DOI: 10.1016/j.pcad.2011.11.003  0.32
2011 Kostis JB, Cabrera J, Cheng JQ, Cosgrove NM, Deng Y, Pressel SL, Davis BR. Association between chlorthalidone treatment of systolic hypertension and long-term survival. Jama. 306: 2588-93. PMID 22187278 DOI: 10.1001/jama.2011.1821  0.32
2011 Piller LB, Baraniuk S, Simpson LM, Cushman WC, Massie BM, Einhorn PT, Oparil S, Ford CE, Graumlich JF, Dart RA, Parish DC, Retta TM, Cuyjet AB, Jafri SZ, Furberg CD, ... ... Davis BR, et al. Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation. 124: 1811-8. PMID 21969009 DOI: 10.1161/CIRCULATIONAHA.110.012575  0.32
2011 Tanner RM, Lynch AI, Brophy VH, Eckfeldt JH, Davis BR, Ford CE, Boerwinkle E, Arnett DK. Pharmacogenetic associations of MMP9 and MMP12 variants with cardiovascular disease in patients with hypertension. Plos One. 6: e23609. PMID 21887284 DOI: 10.1371/journal.pone.0023609  0.32
2011 Sherva R, Ford CE, Eckfeldt JH, Davis BR, Boerwinkle E, Arnett DK. Pharmacogenetic effect of the stromelysin (MMP3) polymorphism on stroke risk in relation to antihypertensive treatment: the genetics of hypertension associated treatment study. Stroke; a Journal of Cerebral Circulation. 42: 330-5. PMID 21183746 DOI: 10.1161/STROKEAHA.110.593798  0.32
2010 Couch RB, Davis BR. Has oseltamivir been shown to be effective for treatment of H5N1 influenza? The Journal of Infectious Diseases. 202: 1149-51. PMID 20831386 DOI: 10.1086/656317  0.32
2010 Irvin MR, Lynch AI, Kabagambe EK, Tiwari HK, Barzilay JI, Eckfeldt JH, Boerwinkle E, Davis BR, Ford CE, Arnett DK. Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study. Journal of Hypertension. 28: 2076-83. PMID 20577119 DOI: 10.1097/HJH.0b013e32833c7a4d  0.32
2010 Einhorn PT, Davis BR, Wright JT, Rahman M, Whelton PK, Pressel SL. ALLHAT: still providing correct answers after 7 years. Current Opinion in Cardiology. 25: 355-65. PMID 20520537 DOI: 10.1097/HCO.0b013e32833a8828  0.32
2010 Stafford RS, Bartholomew LK, Cushman WC, Cutler JA, Davis BR, Dawson G, Einhorn PT, Furberg CD, Piller LB, Pressel SL, Whelton PK. Impact of the ALLHAT/JNC7 Dissemination Project on thiazide-type diuretic use. Archives of Internal Medicine. 170: 851-8. PMID 20498411 DOI: 10.1001/archinternmed.2010.130  0.32
2010 Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, ... Davis BR, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 375: 735-42. PMID 20167359 DOI: 10.1016/S0140-6736(09)61965-6  0.32
2010 Yeh HW, Chan W, Symanski E, Davis BR. Estimating transition probabilities for ignorable intermittent missing data in a discrete-time markov chain Communications in Statistics: Simulation and Computation. 39: 433-448. DOI: 10.1080/03610910903480800  0.32
2009 Haywood LJ, Ford CE, Crow RS, Davis BR, Massie BM, Einhorn PT, Williard A. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). Journal of the American College of Cardiology. 54: 2023-31. PMID 19926008 DOI: 10.1016/j.jacc.2009.08.020  0.32
2009 Grimm RH, Davis BR, Piller LB, Cutler JA, Margolis KL, Barzilay J, Dart RA, Graumlich JF, Murden RA, Randall OS. Heart failure in ALLHAT: did blood pressure medication at study entry influence outcome? Journal of Clinical Hypertension (Greenwich, Conn.). 11: 466-74. PMID 19751458 DOI: 10.1111/j.1751-7176.2009.00149.x  0.32
2009 Khoury MJ, McBride CM, Schully SD, Ioannidis JP, Feero WG, Janssens AC, Gwinn M, Simons-Morton DG, Bernhardt JM, Cargill M, Chanock SJ, Church GM, Coates RJ, Collins FS, Croyle RT, ... Davis BR, et al. The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 11: 559-67. PMID 19617843 DOI: 10.1097/GIM.0b013e3181b13a6c  0.32
2009 Bartholomew LK, Cushman WC, Cutler JA, Davis BR, Dawson G, Einhorn PT, Graumlich JF, Piller LB, Pressel S, Roccella EJ, Simpson L, Whelton PK, Williard A, Allhat Collaborative Research Group. Getting clinical trial results into practice: design, implementation, and process evaluation of the ALLHAT Dissemination Project. Clinical Trials (London, England). 6: 329-43. PMID 19587068 DOI: 10.1177/1740774509338234  0.32
2009 Wright JT, Probstfield JL, Cushman WC, Pressel SL, Cutler JA, Davis BR, Einhorn PT, Rahman M, Whelton PK, Ford CE, Haywood LJ, Margolis KL, Oparil S, Black HR, Alderman MH, et al. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Archives of Internal Medicine. 169: 832-42. PMID 19433694 DOI: 10.1001/archinternmed.2009.60  0.32
2009 Maitland-van der Zee AH, Peters BJ, Lynch AI, Boerwinkle E, Arnett DK, Cheng S, Davis BR, Leiendecker-Foster C, Ford CE, Eckfeldt JH. The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13 ) on the effectiveness of statins: the GenHAT study. Pharmacogenetics and Genomics. 19: 338-44. PMID 19415820 DOI: 10.1097/FPC.0b013e32832933b7  0.32
2009 Lynch AI, Boerwinkle E, Davis BR, Ford CE, Eckfeldt JH, Leiendecker-Foster C, Arnett DK. Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study. Pharmacogenetics and Genomics. 19: 415-21. PMID 19352213 DOI: 10.1097/FPC.0b013e32832a8e81  0.32
2009 Davis BR, Whelton PK. Benazepril plus amlodipine or hydrochlorothiazide for hypertension. The New England Journal of Medicine. 360: 1148-9; author reply. PMID 19283889  0.32
2009 Davis BR, Simpson LM, Ford CE, Kostis JB, Black HR, Cushman WC, Einhorn PT, Farber MA, Levy D, Massie BM, Nawaz S. Response to letter regarding article, "Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial" Circulation. 120: e32. DOI: 10.1161/CIRCULATIONAHA.109.854562  0.32
2008 Nwachuku CE, Bastien A, Cutler JA, Grob GM, Margolis KL, Roccella EJ, Pressel S, Davis BR, Caso M, Sheps S, Weber M. Management of high blood pressure in clinical practice: perceptible qualitative differences in approaches utilized by clinicians. Journal of Clinical Hypertension (Greenwich, Conn.). 10: 822-9. PMID 19128270 DOI: 10.1111/j.1751-7176.2008.00035.x  0.32
2008 Cushman WC, Ford CE, Einhorn PT, Wright JT, Preston RA, Davis BR, Basile JN, Whelton PK, Weiss RJ, Bastien A, Courtney DL, Hamilton BP, Kirchner K, Louis GT, Retta TM, et al. Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Journal of Clinical Hypertension (Greenwich, Conn.). 10: 751-60. PMID 19090876 DOI: 10.1111/j.1751-7176.2008.00015.x  0.32
2008 Davis BR, Kostis JB, Simpson LM, Black HR, Cushman WC, Einhorn PT, Farber MA, Ford CE, Levy D, Massie BM, Nawaz S. Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation. 118: 2259-67. PMID 19001024 DOI: 10.1161/CIRCULATIONAHA.107.762229  0.32
2008 Rahman M, Baimbridge C, Davis BR, Barzilay J, Basile JN, Henriquez MA, Huml A, Kopyt N, Louis GT, Pressel SL, Rosendorff C, Sastrasinh S, Stanford C. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 52: 412-24. PMID 18676075 DOI: 10.1053/j.ajkd.2008.05.027  0.32
2008 Maitland-van der Zee AH, Lynch A, Boerwinkle E, Arnett DK, Davis BR, Leiendecker-Foster C, Ford CE, Eckfeldt JH. Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study. Pharmacogenetics and Genomics. 18: 651-6. PMID 18622257 DOI: 10.1097/FPC.0b013e3282fe1759  0.32
2008 Patel AB, Kostis JB, Wilson AC, Shea ML, Pressel SL, Davis BR. Long-term fatal outcomes in subjects with stroke or transient ischemic attack: fourteen-year follow-up of the systolic hypertension in the elderly program. Stroke; a Journal of Cerebral Circulation. 39: 1084-9. PMID 18309155 DOI: 10.1161/STROKEAHA.107.500777  0.32
2008 Heidenreich PA, Davis BR, Cutler JA, Furberg CD, Lairson DR, Shlipak MG, Pressel SL, Nwachuku C, Goldman L. Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Journal of General Internal Medicine. 23: 509-16. PMID 18228109 DOI: 10.1007/s11606-008-0515-2  0.32
2008 Wright JT, Harris-Haywood S, Pressel S, Barzilay J, Baimbridge C, Bareis CJ, Basile JN, Black HR, Dart R, Gupta AK, Hamilton BP, Einhorn PT, Haywood LJ, Jafri SZ, Louis GT, ... ... Davis BR, et al. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Archives of Internal Medicine. 168: 207-17. PMID 18227370 DOI: 10.1001/archinternmed.2007.66  0.32
2008 Lynch AI, Boerwinkle E, Davis BR, Ford CE, Eckfeldt JH, Leiendecker-Foster C, Arnett DK. Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. Jama. 299: 296-307. PMID 18212314 DOI: 10.1001/jama.299.3.296  0.32
2008 Black HR, Davis B, Barzilay J, Nwachuku C, Baimbridge C, Marginean H, Wright JT, Basile J, Wong ND, Whelton P, Dart RA, Thadani U. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care. 31: 353-60. PMID 18000186 DOI: 10.2337/dc07-1452  0.32
2008 Kostis JB, Pressel SL, Davis BR. Response to letter by bath et al Stroke. 39. DOI: 10.1161/STROKEAHA.108.527325  0.32
2007 Lynch AI, Arnett DK, Davis BR, Boerwinkle E, Ford CE, Eckfeldt JH, Leiendecker-Foster C. Sex-specific effects of AGT-6 and ACE I/D on pulse pressure after 6 months on antihypertensive treatment: The GenHAT Study Annals of Human Genetics. 71: 735-745. PMID 17608790 DOI: 10.1111/j.1469-1809.2007.00381.x  0.32
2007 Barzilay JI, Cutler JA, Davis BR. Antihypertensive medications and risk of diabetes mellitus. Current Opinion in Nephrology and Hypertension. 16: 256-60. PMID 17420670 DOI: 10.1097/MNH.0b013e328057dea2  0.32
2007 Maitland-van der Zee AH, Boerwinkle E, Arnett DK, Davis BR, Leiendecker-Foster C, Miller MB, Klungel OH, Ford CE, Eckfeldt JH. Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) study. American Heart Journal. 153: 54-8. PMID 17174637 DOI: 10.1016/j.ahj.2006.10.019  0.32
2007 Einhorn PT, Davis BR, Massie BM, Cushman WC, Piller LB, Simpson LM, Levy D, Nwachuku CE, Black HR. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis. American Heart Journal. 153: 42-53. PMID 17174636 DOI: 10.1016/j.ahj.2006.10.012  0.32
2007 Davis BR, Arnett DK, Boerwinkle E, Ford CE, Leiendecker-Foster C, Miller MB, Black H, Eckfeldt JH. Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study. The Pharmacogenomics Journal. 7: 112-22. PMID 16702981 DOI: 10.1038/sj.tpj.6500395  0.32
2007 Davis BR, Piller LB, Dunn K, Cutler JA, Proschan M, Furberg C, Goff D, Franklin S, Leenen F, Mohiuddin S, Papademetriou V, Ellsworth A, Golden J, Colon P, Crow R. Response to letter regarding article, "role of diuretics in the prevention of heart failure: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)" [2] Circulation. 115. DOI: 10.1161/CIRCULATIONAHA.106.651539  0.32
2007 Davis BR, Baraniuk S. 18 Definitive Phase III and Phase IV Clinical Trials Handbook of Statistics. 27: 546-568. DOI: 10.1016/S0169-7161(07)27018-X  0.32
2006 Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, Margolis KL, Ong ST, Sadler LS, Summerson J. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Archives of Internal Medicine. 166: 2191-201. PMID 17101936 DOI: 10.1001/archinte.166.20.2191  0.32
2006 Piller LB, Ford CE, Davis BR, Nwachuku C, Black HR, Oparil S, Retta TM, Probstfield JL. Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Journal of Clinical Hypertension (Greenwich, Conn.). 8: 649-56; quiz 657-8. PMID 16957427  0.32
2006 Leenen FH, Nwachuku CE, Black HR, Cushman WC, Davis BR, Simpson LM, Alderman MH, Atlas SA, Basile JN, Cuyjet AB, Dart R, Felicetta JV, Grimm RH, Haywood LJ, Jafri SZ, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 48: 374-84. PMID 16864749 DOI: 10.1161/01.HYP.0000231662.77359.de  0.32
2006 Rahman M, Nwachuku C, Whelton P, Probstfield J, Davis BR. Re: Hawkins RG, Houston MC Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the United States? A hypothesis. Am J Hypertens. 2005 Jun;18(6):744-9. American Journal of Hypertension. 19: 656-7. PMID 16733244 DOI: 10.1016/j.amjhyper.2005.09.008  0.32
2006 Davis BR, Piller LB, Cutler JA, Furberg C, Dunn K, Franklin S, Goff D, Leenen F, Mohiuddin S, Papademetriou V, Proschan M, Ellsworth A, Golden J, Colon P, Crow R, et al. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation. 113: 2201-10. PMID 16651474 DOI: 10.1161/CIRCULATIONAHA.105.544031  0.32
2006 Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber MA, Franklin S, Henriquez M, Kopyt N, Louis GT, Saklayen M, et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Annals of Internal Medicine. 144: 172-80. PMID 16461961  0.32
2006 Davis BR, Cutler JA. Data monitoring in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Early termination of the doxazosin treatment arm Data Monitoring in Clinical Trials: a Case Studies Approach. 248-259. DOI: 10.1007/0-387-30107-0_23  0.32
2005 Whelton PK, Barzilay J, Cushman WC, Davis BR, Iiamathi E, Kostis JB, Leenen FH, Louis GT, Margolis KL, Mathis DE, Moloo J, Nwachuku C, Panebianco D, Parish DC, Pressel S, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Archives of Internal Medicine. 165: 1401-9. PMID 15983290 DOI: 10.1001/archinte.165.12.1401  0.32
2005 Arnett DK, Davis BR, Ford CE, Boerwinkle E, Leiendecker-Foster C, Miller MB, Black H, Eckfeldt JH. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation. 111: 3374-83. PMID 15967849 DOI: 10.1161/CIRCULATIONAHA.104.504639  0.32
2005 Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber M, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Archives of Internal Medicine. 165: 936-46. PMID 15851647 DOI: 10.1001/archinte.165.8.936  0.32
2005 Wright JT, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, Haywood LJ, Leenen FH, Margolis KL, Papademetriou V, Probstfield JL, Whelton PK, Habib GB. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. Jama. 293: 1595-608. PMID 15811979 DOI: 10.1001/jama.293.13.1595  0.32
2005 Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. The American Journal of Cardiology. 95: 29-35. PMID 15619390 DOI: 10.1016/j.amjcard.2004.08.059  0.32
2004 Dickersin K, Davis BR, Dixon DO, George SL, Hawkinse BS, Lachin J, Peduzzi P, Pocock S. The Society for Clinical Trials supports United States legislation mandating trials registration. Position paper. Clinical Trials (London, England). 1: 417-20. PMID 16279279 DOI: 10.1191/1740774504cn039oa  0.32
2004 Schabath MB, Grossman HB, Delclos GL, Hernandez LM, Day RS, Davis BR, Lerner SP, Spitz MR, Wu X. Dietary carotenoids and genetic instability modify bladder cancer risk. The Journal of Nutrition. 134: 3362-9. PMID 15570038 DOI: 10.1093/jn/134.12.3362  0.32
2004 Best PJ, Berger PB, Davis BR, Grines CL, Sadeghi HM, Williams BA, Willerson JT, Granett JR, Holmes DR. Impact of mild or moderate chronic kidney disease on the frequency of restenosis: results from the PRESTO trial. Journal of the American College of Cardiology. 44: 1786-91. PMID 15519008 DOI: 10.1016/j.jacc.2004.07.052  0.32
2004 Davis BR, Ford CE, Boerwinkle E, Arnett D, Eckeldt J, Black H. Imputing gene-treatment interactions when the genotype distribution is unknown using case-only and putative placebo analyses - A new method for the Genetics of Hypertension Associated Treatment (GenHAT) study Statistics in Medicine. 23: 2413-2427. PMID 15273956 DOI: 10.1002/sim.1831  0.32
2004 Davis BR, Furberg CD, Wright JT, Cutler JA, Whelton P. ALLHAT: Setting the record straight Annals of Internal Medicine. 141: 39-46. PMID 15238369 DOI: 10.7326/0003-4819-141-1-200407060-00013  0.32
2004 Rahman M, Brown CD, Coresh J, Davis BR, Eckfeldt JH, Kopyt N, Levey AS, Nwachuku C, Pressel S, Reisin E, Walworth C. The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Archives of Internal Medicine. 164: 969-76. PMID 15136305 DOI: 10.1001/archinte.164.9.969  0.32
2004 Barzilay JI, Davis BR, Bettencourt J, Margolis KL, Goff DC, Black H, Habib G, Ellsworth A, Force RW, Wiegmann T, Ciocon JO, Basile JN. Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study Journal of Clinical Hypertension (Greenwich, Conn.). 6: 116-125. PMID 15010644 DOI: 10.1111/j.1524-6175.2004.03216.x  0.32
2002 Furberg CD, Wright JT, Davis BR, Cutler JA, Alderman M, Black H, Cushman W, Grimm R, Haywood LJ, Leenen F, Oparil S, Probstfield J, Whelton P, Nwachuku C, Gordon D, et al. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT) Journal of the American Medical Association. 288: 2998-3007. PMID 12479764 DOI: 10.1001/jama.288.23.2998  0.32
2002 Furberg CD, Wright JT, Davis BR, Cutler JA, Alderman M, Black H, Cushman W, Grimm R, Haywood LJ, Leenen F, Oparil S, Probstfield J, Whelton P, Nwachuku C, Gordon D, et al. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) Journal of the American Medical Association. 288: 2981-2997. PMID 12479763 DOI: 10.1001/jama.288.23.2981  0.32
2002 Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT, Alderman MH, Weiss RJ, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Journal of Clinical Hypertension (Greenwich, Conn.). 4: 393-404. PMID 12461301 DOI: 10.1111/j.1524-6175.2002.02045.x  0.32
2002 Piller LB, Davis BR, Cutler JA, Cushman WC, Wright JT, Williamson JD, Leenen FH, Einhorn PT, Randall OS, Golden JS, Haywood LJ. Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone. Current Controlled Trials in Cardiovascular Medicine. 3: 10. PMID 12459039 DOI: 10.1186/1468-6708-3-10  0.32
2002 Davis BR, Cutler JA, Furberg CD, Wright JT, Farber MA, Felicetta JV, Stokes JD. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. Annals of Internal Medicine. 137: 313-20. PMID 12204014 DOI: 10.7326/0003-4819-137-5_Part_1-200209030-00006  0.32
2001 Wright JT, Cushman WC, Davis BR, Barzilay J, Colon P, Egan D, Lucente T, Nwachuku C, Pressel S, Leenen FH, Frolkis J, Letterer R, Walsh S, Tobin JN, Deger GE, et al. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): clinical center recruitment experience. Controlled Clinical Trials. 22: 659-73. PMID 11738122 DOI: 10.1016/S0197-2456(01)00176-3  0.32
2001 Pressel SL, Davis BR, Wright JT, Geraci TS, Kingry C, Ford CE, Piller LB, Bettencourt J, Kimmel B, Lusk C, Parks H, Simpson LM, Nwachuku C, Furberg CD. Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Controlled Clinical Trials. 22: 29-41. PMID 11165421 DOI: 10.1016/S0197-2456(00)00109-4  0.32
1999 Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, Cuddy TE, Moyé LA, Piller LB, Rutherford J, Simpson LM, Braunwald E. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation. 99: 216-23. PMID 9892586 DOI: 10.1161/01.CIR.99.2.216  0.32
1998 Goldberg RB, Mellies MJ, Sacks FM, Moyé LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the Cholesterol And Recurrent Events (CARE) trial Circulation. 98: 2513-2519. PMID 9843456 DOI: 10.1161/01.CIR.98.23.2513  0.32
1998 Lewis SJ, Moye LA, Sacks FM, Johnstone DE, Timmis G, Mitchell J, Limacher M, Kell S, Glasser SP, Grant J, Davis BR, Pfeffer MA, Braunwald E. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: Results of the cholesterol and recurrent events (CARE) trial Annals of Internal Medicine. 129: 681-689. PMID 9841599 DOI: 10.7326/0003-4819-129-9-199811010-00002  0.32
1998 Davis BR, Vogt T, Frost PH, Burlando A, Cohen J, Wilson A, Brass LM, Frishman W, Price T, Stamler J. Risk factors for stroke and type of stroke in persons with isolated systolic hypertension Stroke. 29: 1333-1340. PMID 9660383 DOI: 10.1161/01.STR.29.7.1333  0.32
1998 Savage PJ, Pressel SL, David Curb J, Schron EB, Applegate WB, Black HR, Cohen J, Davis BR, Frost P, Smith W, Gonzalez N, Guthrie GP, Oberman A, Rutan G, Probstfreld JL, et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program Archives of Internal Medicine. 158: 741-751. PMID 9554680 DOI: 10.1001/archinte.158.7.741  0.32
1998 Hager WD, Davis BR, Riba A, Moye LA, Wun CC, Rouleau JL, Lamas GA, Pfeffer MA. Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: The SAVE Study Experience. SAVE Investigators. Survival and Ventricular Enlargement. American Heart Journal. 135: 406-13. PMID 9506325 DOI: 10.1016/S0002-8703(98)70315-1  0.32
1998 Fuller LM, Mirza NQ, Palmer JL, Davis BR, Ha. CS, Rodriguez MA, Hagemeister FB, Cabanillas F, McLaughlin P, Butler JJ, North LB, Martin RG. Hodgkin's disease: Correlation of clinical characteristics with probabilities for negative lymphangiogram vs. negative laparotomy findings in patients with stage I supradiaphragmatic presentations vs. those in patients with stage II International Journal of Radiation Oncology Biology Physics. 40: 377-386. PMID 9457824 DOI: 10.1016/S0360-3016(97)00712-8  0.32
1997 Hardy RJ, Palmer EA, Schaffer DB, Phelps DL, Davis BR, Cooper CJ. Outcome-based management of retinopathy of prematurity Journal of Aapos. 1: 46-54. PMID 10530985 DOI: 10.1016/S1091-8531(97)90023-9  0.32
1996 Frost PH, Davis BR, Burlando AJ, Curb JD, Guthrie GP, Isaacsohn JL, Wassertheil-Smoller S, Wilson AC, Stamler J. Coronary heart disease risk factors in men and women aged 60 years and older: findings from the Systolic Hypertension in the Elderly Program. Circulation. 94: 26-34. PMID 8964114 DOI: 10.1161/01.CIR.94.1.26  0.32
1996 Frost PH, Davis BR, Burlando AJ, Curb JD, Guthrie GP, Isaacsohn JL, Wassertheil-Smoller S, Wilson AC, Stamler J. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation. 94: 2381-8. PMID 8921777 DOI: 10.1161/01.CIR.94.10.2381  0.32
1996 Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. The New England Journal of Medicine. 335: 1001-9. PMID 8801446 DOI: 10.1056/NEJM199610033351401  0.32
1996 Whelton PK, Williamson JD, Louis GT, Davis BR, Cutler JA. Experimental approaches to determining the choice of first-step therapy for patients with hypertension Clinical and Experimental Hypertension. 18: 569-579. PMID 8743044 DOI: 10.3109/10641969609088986  0.32
1996 Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT, Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil S, Francis C, Proschan M, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. American Journal of Hypertension. 9: 342-60. PMID 8722437 DOI: 10.1016/0895-7061(96)00037-4  0.32
1994 Moye LA, Pfeffer MA, Wun CC, Davis BR, Geltman E, Hayes D, Farnham DJ, Randall OS, Dinh H, Arnold JMO, Kupersmth J, Hager D, Glasser SP, Biddle T, Hawkins CM, et al. Uniformity of captopril benefit in the SAVE study: Subgroup analysis European Heart Journal. 15: 2-8. PMID 8076658 DOI: 10.1093/eurheartj/15.suppl_B.2  0.32
1994 Rutherford JD, Pfeffer MA, Moyé LA, Davis BR, Flaker GC, Kowey PR, Lamas GA, Miller HS, Packer M, Rouleau JL. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation. 90: 1731-8. PMID 7923656 DOI: 10.1161/01.CIR.90.4.1731  0.32
1993 Davis BR, Blaufox MD, Oberman A, Wassertheil-Smoller S, Zimbaldi N, Cutler JA, Kirchner K, Langford HG. Reduction in long-term antihypertensive medication requirements. Effects of weight reduction by dietary intervention in overweight persons with mild hypertension. Archives of Internal Medicine. 153: 1773-82. PMID 8333814 DOI: 10.1001/archinte.1993.00410150051005  0.32
1992 Loewy JW, Kapadia AS, Hsi B, Davis BR. Statistical Methods That Distinguish between Attributes of Assessment:Prolongation of Life versus Quality of Life Medical Decision Making. 12: 83-92. PMID 1573984 DOI: 10.1177/0272989X9201200201  0.32
1992 Davis BR, Oberman A, Donald Blaufox M, Wassertheil-Smoller S, Morton Hawkins C, Cutler JA, Zimbaldi N, Langford HG. Effect of antihypertensive therapy on weight loss Hypertension. 19: 393-399. PMID 1555871 DOI: 10.1161/01.HYP.19.4.393  0.32
1992 Moye LA, Davis BR, Hawkins CM. Analysis of a clinical trial involving a combined mortality and adherence dependent interval censored endpoint Statistics in Medicine. 11: 1705-1717. PMID 1485054 DOI: 10.1002/sim.4780111305  0.32
1992 Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial New England Journal of Medicine. 327: 669-677. PMID 1386652 DOI: 10.1056/NEJM199209033271001  0.32
1991 Quinn GE, Dobson V, Barr CC, Davis BR, Flynn JT, Palmer EA, Robertson J, Trese MT. Visual acuity in infants after vitrectomy for severe retinopathy of prematurity. Ophthalmology. 98: 5-13. PMID 2023732 DOI: 10.1016/S0161-6420(91)32343-1  0.32
1991 Wassertheil-Smoller S, Blaufox MD, Oberman A, Davis BR, Swencionis C, Knerr MO, Hawkins CM, Langford HG. Effect of antihypertensives on sexual function and quality of life: the TAIM Study. Annals of Internal Medicine. 114: 613-20. PMID 2003706 DOI: 10.7326/0003-4819-114-8-613  0.32
1991 Applegate WB, Davis BR, Black HR, Smith WM, Miller ST, Burlando AJ. Prevalence of postural hypotension at baseline in the systolic hypertension in the elderly program (SHEP) cohort Journal of the American Geriatrics Society. 39: 1057-1064. PMID 1753042 DOI: 10.1111/j.1532-5415.1991.tb02869.x  0.32
1991 Hardy RJ, Davis BR, Palmer EA, Tung B. Statistical considerations in terminating randomization in the multicenter trial of cryotherapy for retinopathy of prematurity Controlled Clinical Trials. 12: 293-303. PMID 1645641 DOI: 10.1016/0197-2456(91)90026-I  0.32
1991 Palmer EA, Hardy RJ, Davis BR, Stein JA, Mowery RL, Tung B, Phelps DL, Schaffer DB, Flynn JT, Phillips CL. Operational aspects of terminating randomization in the multicenter trial of cryotherapy for retinopathy of prematurity Controlled Clinical Trials. 12: 277-292. PMID 1645640 DOI: 10.1016/0197-2456(91)90025-H  0.32
1991 Stamler J, Berge KG, Davis BR, Hadley E, Pressel S, Probstfield J. In Reply Jama: the Journal of the American Medical Association. 266: 2829-2830. DOI: 10.1001/jama.1991.03470200041014  0.32
1988 Shulman N, Tuttle E, Entwisle G, Apostolides A, Oberman A, Schnaper HW, Kass EH, Taylor JO, Polk BF, Stamler J, Stamler R, Gosch F, Borhani NO, Newman B, Harlan L, ... ... Davis BR, et al. Persistence of Reduction in Blood Pressure and Mortality of Participants in the Hypertension Detection and Follow-up Program Jama: the Journal of the American Medical Association. 259: 2113-2122. PMID 3346988 DOI: 10.1001/jama.1988.03720140033030  0.32
1986 Davis BR, Ford CE, Remington RD, Stamler R, Morton Hawkins C. The hypertension detection and follow-up program design, methods, and baseline characteristics and blood pressure response of the study population Progress in Cardiovascular Diseases. 29: 11-28. PMID 3538177 DOI: 10.1016/0033-0620(86)90032-0  0.32
1985 Curb JD, Davis BR, Tung B. Standardized physician preparation of death certificates Controlled Clinical Trials. 6: 237. DOI: 10.1016/0197-2456(87)90036-5  0.32
Show low-probability matches.